Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $662,250.96 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,592 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares of the company’s stock, valued at $4,012,354.16. This represents a 14.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.72, for a total value of $669,263.40.
• On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.20, for a total value of $5,117,000.00.
• On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16.
• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.69, for a total value of $505,973.89.

Hims & Hers Health Trading Down 3.9%

Shares of HIMS stock opened at $47.45 on Thursday. The company has a 50-day moving average of $51.05 and a two-hundred day moving average of $49.20. The firm has a market cap of $10.72 billion, a PE ratio of 59.31, a price-to-earnings-growth ratio of 3.42 and a beta of 2.25. Hims & Hers Health, Inc. has a 1-year low of $18.33 and a 1-year high of $72.98. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the previous year, the business posted $0.06 EPS. The business’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several research reports. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research note on Friday, September 12th. Weiss Ratings reissued a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, KeyCorp started coverage on Hims & Hers Health in a research report on Tuesday. They set a “sector weight” rating on the stock. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $38.92.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its position in shares of Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after acquiring an additional 2,128,587 shares in the last quarter. Nuveen LLC acquired a new position in Hims & Hers Health in the first quarter valued at approximately $58,403,000. Clear Street LLC purchased a new position in Hims & Hers Health in the second quarter valued at approximately $83,582,000. Norges Bank acquired a new stake in Hims & Hers Health during the second quarter worth approximately $78,464,000. Finally, Marex Group plc purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $53,626,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.